All Products
Showing 901–919 of 919 results
Yellow Fever Virus Vaccine Serum: 12-Month (IgG) Bleed
Yellow Fever Virus donor serum obtained from a recipient of Yellow Fever vaccine (17D strain), 12 months post immunisation.
Yellow Fever Virus Vaccine Serum: 2-Week (IgM) Bleed
Unique panel of Yellow Fever Virus donor serum, from a panel of donors immunised with the Yellow Fever vaccine, Stamaril. Samples are available from each donor prior to vaccination, and at 2-week and 6-week time points, to allow for assessment of IgM and IgG responses across broad response profiles. See donor selection table for donor details and travel history.
Yellow Fever Virus Vaccine Serum: 6-Month (IgG) Bleed
Yellow Fever Virus donor serum obtained from a recipient of Yellow Fever vaccine (17D strain), 6 months post immunisation.
Yellow Fever Virus Vaccine Serum: 6-Week (IgG) Bleed
unique panel of Yellow Fever Virus donor serum, from a panel of donors immunised with the Yellow Fever vaccine, Stamaril. Samples are available from each donor prior to vaccination, and at 2-week and 6-week time points, to allow for assessment of IgM and IgG responses across broad response profiles. See donor selection table for donor details and travel history.
Yellow Fever Virus Vaccine Serum: Pre-Vaccination Bleed
Yellow Fever Virus Donor Serum from pre-vaccination bleed. See donor selection table for donor details and travel history.
Yellow Fever Virus Vaccine Serum: Vaccination Time-Course Panel
Yellow Fever Virus Vaccine Serum triple pack of samples from an individual who was immunised with the Yellow Fever vaccine Stamaril (17D strain). The first vial is a pre-bleed sample, taken one week before the immunisation. The second vial is an “IgM” vial, taken 2 weeks post immunisation. The third vial is an “IgG” vial taken 6 weeks post immunisation.
Yersinia Enterocolitica Cells, Heat-Inactivated
Heat-killed Yersinia enterocolitica cells in dextran solution. Antigen is intended for use as a positive control in immunoassay development for Yersinia detection. Part of the BacTrace® range of antigens and antibodies.
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag
Our Yersinia pestis chain B F1 capsule antigen, purified from inclusion bodies using immobilised metal affinity chromatography and dialysis, allows for further research into the immunisation strategy of this re-emerging infectious disease and the development of efficient, rapid diagnostic tools.
Yersinia pestis V antigen
Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product.
Zika Virus DIII Envelope Protein (Asian Strain)
Recombinant Zika Virus domain III (DIII) Envelope protein (Asian strain), produced in E. coli at
Zika Virus Envelope Protein (Suriname strain)
Recombinant Zika virus envelope protein expressed in HEK293 mammalian cells, with C terminal 6-His tag.
Zika Virus Lysate (PRVABC59 Strain)
Purified heat inactivated Lysate of native Zika virus (PRVABC59 strain) infected LLC-mk2 or Vero cells.
Zika Virus NS1 Protein (Suriname Strain)
Recombinant Zika Virus (Suriname strain) NS1 protein, incorporating a C-terminal 6x His tag produced in mammalian HEK293 cells.
Zika Virus NS1 Protein (Uganda Strain)
Recombinant Zika Virus (Uganda strain) NS1 protein, incorporating a C-terminal 6x His tag produced in mammalian HEK293 cells.
Zika Virus NS1 Proteins (Uganda/Suriname Strains Duo Pack)
Recombinant Zika Virus NS1 protein, with C-terminal 6xHis tags, produced in mammalian HEK293 ells. One vial each of Zika NS1 from Suriname and Uganda strains.
Zika Virus Total Antibody Detection Assay Development Kit
The Native Antigen Company Zika virus total antibody assay development kit is designed to aid in the development of assays for the detection of Zika-specific antibodies in human serum. It is minimally cross-reactive with antibodies to Dengue virus (a closely-related flavivirus), and so can be used to develop assays which can distinguish human anti-Zika antibodies from other flavivirus and infectious disease antibodies, especially in epidemiological studies. Use of a Zika antibody assay is intended for detection of IgG in convalescent sera, although IgM/IgA are also detected earlier on in the infection cycle.
Zika Virus Vero Cell Lysate
Lysate of native Zika virus infected Vero cells.
Zika Virus VLP
Recombinant Zika virus-like particles consisting of Envelope, pre-Membrane and Membrane protein produced in mammalian HEK293 human cells.
Zika virus-like particles, immature
Zika virus-like particles (VLPs) expressed in HEK293 cells and purified from cultrue supernatant; The furin cleavage site in the prM protein has been altered and inactivated. This product is especially recommended for diagnostic assay developers, as it is ideal for sensitive assays.
Powered by Bioz